{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:42:41Z","timestamp":1785300161620,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016819","name":"Octapharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtha.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T15:10:10Z","timestamp":1728745810000},"page":"85-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-3424","authenticated-orcid":false,"given":"Behnaz","family":"Pezeshkpoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Sereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Becker-Gotot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Cristin","family":"Berkemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Matuschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samhitha Urs","family":"Ramaraje Urs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Marquardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.10.003_bib1","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Huth-K\u00fchne","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.10.003_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.5482\/HAMO-14-11-0064","article-title":"Management of acquired haemophilia A","volume":"35","author":"Tiede","year":"2015","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s40265-018-1027-y","article-title":"Prevention and management of bleeding episodes in patients with acquired hemophilia A","volume":"78","author":"Kn\u00f6bl","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.14618","article-title":"Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01\/2010 Study","volume":"18","author":"T\u00fcrkantoz","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/a-1171-0522","article-title":"Critical bleeding in acquired hemophilia A: bypassing agents or recombinant porcine factor VIII?","volume":"41","author":"Tiede","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A\u00a0bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2024.10.003_bib9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A\u00a0first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.003_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.10.003_bib12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.10.003_bib13","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.003_bib14","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/jth.14957","article-title":"Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: new case with detailed laboratory evaluation","volume":"18","author":"Harkins Druzgal","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102194","article-title":"Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: case report of a first noninhibitor patient and review of the literature","volume":"7","author":"Kizilocak","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1111\/jth.15506","article-title":"Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A","volume":"19","author":"Kaneda","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3324\/haematol.2021.278579","article-title":"Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient","volume":"106","author":"Harroche","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000497287","article-title":"Emicizumab in the treatment of acquired haemophilia: a case report","volume":"46","author":"M\u00f6hnle","year":"2019","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.jtha.2024.10.003_bib20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/rth2.12201","article-title":"Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention","volume":"3","author":"Dane","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.12659\/AJCR.916783","article-title":"Emicizumab use in treatment of acquired hemophilia A: a case report","volume":"20","author":"Al-Banaa","year":"2019","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jtha.2024.10.003_bib22","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtha.2024.10.003_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics - the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.10.003_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1995929","article-title":"The impact of immunogenicity on therapeutic antibody pharmacokinetics: a preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance","volume":"13","author":"Opolka-Hoffmann","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.jtha.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.jtha.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.yrtph.2009.03.012","article-title":"Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies","volume":"54","author":"Ponce","year":"2009","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.jtha.2024.10.003_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2021.122836","article-title":"Bispecific antibody characterization by a combination of intact and site-specific\/chain-specific LC\/MS techniques","volume":"236","author":"Duivelshof","year":"2022","journal-title":"Talanta"},{"key":"10.1016\/j.jtha.2024.10.003_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/biom9120765","article-title":"The plasma factor XIII heterotetrameric complex structure: unexpected unequal pairing within a symmetric complex","volume":"9","author":"Singh","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.jtha.2024.10.003_bib30","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/jth.15665","article-title":"Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID-19 vaccines","volume":"20","author":"Hirsiger","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jtha.2023.03.011","article-title":"Antidrug antibodies against the polyethylene glycol moiety inhibit the procoagulant activity of therapeutic polyethylene glycolated factor VIII","volume":"21","author":"Pezeshkpoor","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jtha.2024.02.016","article-title":"Comprehensive domain-specific analysis and IgG profiling of anti-FVIII antibodies using a bead-based multiplex immunoassay","volume":"22","author":"Pezeshkpoor","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1515\/cclm-2020-0696","article-title":"Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma","volume":"59","author":"Tripodi","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2024.10.003_bib34","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1016\/j.jtha.2023.09.011","article-title":"Functional determination of emicizumab in presence of factor VIII activity","volume":"21","author":"Hamedani","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12725","article-title":"Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: a method validation study","volume":"6","author":"Donners","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/10892532231151528","article-title":"Native Whole Blood (TRUE-NATEM) and Recalcified Citrated Blood (NATEM) Reference Value Validation with ROTEM Delta","volume":"27","author":"Yoon","year":"2023","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jtha.2024.10.003_bib37","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/hae.14363","article-title":"The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Skinner","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.10.003_bib39","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2024.10.003_bib40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/jth.15226","article-title":"Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor","volume":"19","author":"Valsecchi","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib41","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"M\u00fcller","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.29074\/ascls.2019002204","article-title":"Emicizumab and the clinical coagulation laboratory","volume":"33","author":"Nardi","year":"2020","journal-title":"Clin Lab Sci"},{"key":"10.1016\/j.jtha.2024.10.003_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib44","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/ijlh.13384","article-title":"Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab","volume":"43","author":"Miller","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2024.10.003_bib45","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.003_bib46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1532\/IJH97.06222","article-title":"Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review","volume":"85","author":"Yamamoto","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2024.10.003_bib47","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/MBC.0000000000000304","article-title":"The use of intravenous immunoglobulin in immune tolerance induction in inherited haemophilia A: a single-centre experience and a review of literature","volume":"26","author":"Kubisz","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2024.10.003_bib48","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1016\/S0002-9343(91)80147-E","article-title":"Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors","volume":"91","author":"Sultan","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2024.10.003_bib49","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.10.003_bib50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0002-9343(87)90545-6","article-title":"Use of intravenous gamma globulin in children and adolescents with idiopathic thrombocytopenic purpura and other immune thrombocytopenias","volume":"83","author":"Lusher","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2024.10.003_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cells12192417","article-title":"Anti-Inflammatory and immunomodulatory effect of high-dose immunoglobulins in children: from approved indications to off-label use","volume":"12","author":"Conti","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jtha.2024.10.003_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1243787","article-title":"The use of intravenous immunoglobulin in the treatment of Hashimoto's encephalopathy: case based review","volume":"14","author":"\u015eorodoc","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.jtha.2024.10.003_bib53","article-title":"Intravenous immunoglobulin for autoimmune bullous diseases: a case series from a central european referral center","volume":"59","author":"Spa\u0142ek","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2024.10.003_bib54","first-page":"3","article-title":"Advances in the understanding of the mechanism of action of IVIg","volume":"255","author":"Hartung","year":"2008","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jtha.2024.10.003_bib55","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.10.003_bib56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2249.1991.tb05794.x","article-title":"Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases","volume":"86","author":"Kaveri","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtha.2024.10.003_bib57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jtha.2024.10.003_bib58","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.intimp.2005.11.015","article-title":"Adverse events associated with intravenous immunoglobulin therapy","volume":"6","author":"Hamrock","year":"2006","journal-title":"Int Immunopharmacol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624005816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624005816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T03:45:18Z","timestamp":1738208718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624005816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1538783624005816"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.10.003","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}